Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 483-490

  Estey, E ^a   Thall, P F ^a   Pierce, S ^a   Kantarjian, H ^a   Keating, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTHRACYCLINE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RETINOIC ACID; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031017173     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.483     Document Type: Article

References (30)

1. Ghaddar HM, Plunkett W, Kantarjian HM, et al.: Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 8:1269-1274, 1994
2. Head D, Kopecky KJ, Weick J, et al.: Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86:1717-1728, 1995
3. Fenaux P, Le Deley MC, Castaigne S, et al.: Effect of all-transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 82:3241-3249, 1993
4. Fenaux P, Wattel E, Archimbaud E, et al.: Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. Blood 84:666-667, 1994 (letter)
5. Tallman MS, Andersen J, Schiffer CA, et al.: Phase III randomized study of all-trans retinoic acid vs daunorubicin and cytosine arabinoside as induction therapy and ATRA vs observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia. Blood 86:125a, 1995 (Suppl 1; abstr)
6. Kanamaru A, Takemoto Y, Tanimoto M, et al.: All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 85:1202-1206, 1995
7. Frankel SR, Eardley A, Heller G, et al.: All-trans retinoic acid for acute promyelocytic leukemia-results of the New York study. Ann Intern Med 120:278-286, 1994
8. Mitelman F (ed): ISCN (1991): Guidelines for Cancer Cytogenetics, Supplement to An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, S. Karger, 1991
9. Chang KS, Stass SA, Chu DT, et al.: Characterization of a fusion cDNA (RARA/myl) transcribed from the t(15; 17) translocation breakpoint in acute promyelocytic leukemia. Mol Cell Biol 12:800-810, 1992
10. Frankel SR, Eardley A, Lauwers G, et al.: The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 117:292-296, 1992
11. Kantarjian HM, Keating MJ, Walters RS, et al.: Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer 59:1258-1263, 1987
12. Ganem G, Fischer J, Mary M, et al.: Prognostic factors in acute promyelocytic leukemia (APL): A retrospective study of 101 pts treated by DNR containing remission induction regimen. Blood 62:171a, 1983 (suppl, abstr)
13. Keating MJ, Gehan EA, Smith TL, et al.: A strategy for evaluation of new treatments in untreated patients: Application to a clinical trial of AMSA for acute leukemia. J Clin Oncol 5:710-721, 1987
14. Ghaddar H, Pierce S, Kantarjian H, et al.: Amsacrine and continuous infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed AML. Leukemia Lymphoma 22:71-76, 1996
15. Mehta CR: The exact analysis of contingency tables in medical research. Stat Meth Med Res 3:135-156, 1994
16. Kaplan EL, Meier P: Nonparametric estimations from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
18. Harrington D, Fleming TR: A class of rank test procedures for censored survival data. Biometrika 69:133-143, 1982
19. Harrington D, Fleming TR: Counting Processes and Survival Analysis. New York, NY, Wiley, 1991
20. Cox DR: Regression Models and Life Tables (with discussion). J R Stat Soc B 34:187-220, 1972
21. Therneau TM: A package for survival analysis in S. Mayo Clinic Foundation, 1994
22. Therneau TM, Grambsch PM, Fleming TR: Martingale-based residuals for survival models. Biometrika 77:147-160, 1990
23. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526, 1994
24. Pregibon D: Logistic regression diagnostics. Ann Statist 9:705-724, 1981
25. Cleveland WS: Robust locally-weighted regression and smoothing scatterplots. J Am Stat Assoc 74:829-836, 1979
26. Becker RA, Chambers JM, Wilks ARA: The New S Language. Pacific Grove, CA, Wadsworth, 1988
27. Arlin Z, Kempin S, Mertelsmann R, et al.: Primary therapy of acute promyelocytic leukemia: Results of amsacrine- and daunorubicin-based therapy. Blood 63:211-212, 1984
28. Anderlini P, Benjamin R, Wong F, et al.: Idarubicin cardiotoxicity: A retrospective analysis in acute myeloid leukemia and myelodysplasia. J Clin Oncol 13:2827-2834, 1995
29. Fenaux P, Chastang C, Chomienne C, et al.: Treatment of newly diagnosed acute promyelocytic leukemia by all-transretinoic acid combined with chemotherapy: The European experience. Leukemia Lymphoma 16:431-437, 1995
30. Avvisati G, Lo Coco F, Diverio D, et al.: AIDA (All-trans retinoic acid + idarubicin) in newly-diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) pilot study. Blood 88:1390-1398, 1996